These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

814 related articles for article (PubMed ID: 22049582)

  • 1. Re-engineering drug discovery and development.
    FitzGerald GA
    LDI Issue Brief; 2011 Oct; 17(2):1-4. PubMed ID: 22049582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perestroika in pharma: evolution or revolution in drug development?
    FitzGerald GA
    Mt Sinai J Med; 2010; 77(4):327-32. PubMed ID: 20687177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmaceutical sciences in 2020.
    Crommelin D; Stolk P; Besançon L; Shah V; Midha K; Leufkens H
    Nat Rev Drug Discov; 2010 Feb; 9(2):99-100. PubMed ID: 20118959
    [No Abstract]   [Full Text] [Related]  

  • 4. Traditional drug-discovery model ripe for reform.
    Cressey D
    Nature; 2011 Mar; 471(7336):17-8. PubMed ID: 21368796
    [No Abstract]   [Full Text] [Related]  

  • 5. An audience with...Francis Collins. Interviewed by Asher Mullard.
    Collins F
    Nat Rev Drug Discov; 2011 Jan; 10(1):14. PubMed ID: 21151031
    [No Abstract]   [Full Text] [Related]  

  • 6. FDA not NIH can speed new drugs.
    Miller HI
    Nature; 2011 Apr; 472(7342):169. PubMed ID: 21490657
    [No Abstract]   [Full Text] [Related]  

  • 7. The Critical Path Institute's approach to precompetitive sharing and advancing regulatory science.
    Woosley RL; Myers RT; Goodsaid F
    Clin Pharmacol Ther; 2010 May; 87(5):530-3. PubMed ID: 20407457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Industry and regulatory performance in 2012: a year in review.
    Dowden HM; Jahn R; Catka T; Jonsson A; Michael E; Miwa Y; Zinkand W
    Clin Pharmacol Ther; 2013 Sep; 94(3):359-66. PubMed ID: 23657160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reinventing bioinnovation.
    Kaitin KI; Honig PK
    Clin Pharmacol Ther; 2013 Sep; 94(3):279-83. PubMed ID: 23963211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathways across the valley of death: novel intellectual property strategies for accelerated drug discovery.
    Rai AK; Reichman JH; Uhlir PF; Crossman C
    Yale J Health Policy Law Ethics; 2008; 8(1):1-36. PubMed ID: 18564492
    [No Abstract]   [Full Text] [Related]  

  • 11. Universities shun Europe's drug initiative.
    Gilbert N
    Nature; 2010 Jul; 466(7304):306-7. PubMed ID: 20631770
    [No Abstract]   [Full Text] [Related]  

  • 12. Drugs for Neglected Diseases initiative model of drug development for neglected diseases: current status and future challenges.
    Ioset JR; Chang S
    Future Med Chem; 2011 Sep; 3(11):1361-71. PubMed ID: 21879842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Competition: Unlikely partnerships.
    Savage N
    Nature; 2016 May; 533(7602):S56-8. PubMed ID: 27167391
    [No Abstract]   [Full Text] [Related]  

  • 14. Drug development needs a new brand of science.
    Fitzgerald G
    Nature; 2010 Dec; 468(7326):869. PubMed ID: 21164436
    [No Abstract]   [Full Text] [Related]  

  • 15. Lost opportunities.
    Phan P; Wong D
    Nature; 2017 Dec; 552(7683):S18. PubMed ID: 29220004
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmaceuticals and medical devices: business practices. Issue brief.
    Steiner DJ
    Issue Brief Health Policy Track Serv; 2012 Dec; ():1-36. PubMed ID: 23297448
    [No Abstract]   [Full Text] [Related]  

  • 17. Drug discovery: new models for industry-academic partnerships.
    Tralau-Stewart CJ; Wyatt CA; Kleyn DE; Ayad A
    Drug Discov Today; 2009 Jan; 14(1-2):95-101. PubMed ID: 18992364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Making translation work.
    Williams RS; Desmond-Hellmann S
    Science; 2011 Jun; 332(6036):1359. PubMed ID: 21680815
    [No Abstract]   [Full Text] [Related]  

  • 19. Reaping the benefits of biomedical research: partnerships required.
    Portilla LM; Alving B
    Sci Transl Med; 2010 Jun; 2(35):35cm17. PubMed ID: 20538616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Private sector contributions to pharmaceutical science: thirty-five summary case histories.
    Zycher B; DiMasi JA; Milne CP
    Am J Ther; 2010; 17(1):101-20. PubMed ID: 20027102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.